Unveiling 10 Analyst Insights On Zimmer Biomet Holdings
Portfolio Pulse from Benzinga Insights
Zimmer Biomet Holdings (NYSE:ZBH) has received mixed analyst ratings over the last quarter, with 10 analysts offering varied sentiments. The recent ratings show 4 somewhat bullish and 6 indifferent, with no bullish or bearish ratings. The 12-month price target average for ZBH is now $128.8, down from $138.11, indicating a 6.74% decrease. Analysts from firms like RBC Capital, Evercore ISI Group, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth rate of 5.02% as of September 30, 2023, but trails behind industry peers and shows lower profitability and return metrics compared to industry averages.
January 12, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zimmer Biomet Holdings has received a mix of somewhat bullish and indifferent ratings from analysts, with a downward revision in the 12-month price target average to $128.8. The company's financial performance shows revenue growth but lower profitability and return metrics compared to industry averages.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on ZBH's stock price. The revenue growth is positive, but the lower profitability and return metrics compared to industry averages may concern investors. The high relevance is due to the direct mention of ZBH and detailed analyst ratings. The importance is significant as analyst ratings can influence investor sentiment, but not critical as there are no extreme bullish or bearish stances. The confidence level is high due to the clear data provided but not absolute as market conditions can change rapidly.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100